Use: For the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Usual Pediatric Taltz Dose for Plaque Psoriasis Weight less than 25 kg. Dose 40 mg subcutaneously at Week 0, followed by 20mg every 4 weeks thereafter. ...
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with SKYRIZI. Across the Phase 3 psoriasis clinical studies, of the 72 subjects with latent TB who were concurrently treated with SKYRIZI and appropriate TB prophylaxis during the studies, none developed active TB during t...
Pediatric Plaque Psoriasis The safety and effectiveness of COSENTYX have been established for the treatment of moderate to severe PsO in pediatric patients aged 6 years and older who are candidates for systemic therapy or phototherapy [see ADVERSE REACTIONS and Clinical Studies]. Safety and effectivenes...